ON CANCER,
| Home | CANCER NOTES: UNDERSTANDING CANCER--jk | CANCER: a Summary in Scientific American | CANCER NOTES: SELECTED IMPORTANT TECHNICAL TOPICS--jk | Signaling that promotes cancer metastasis | Stem cells & deadly cancers--new findings | Bacteria & Cancer--the Complex Ecology | CHEMOBRAIN: Cognifitive impairment from chemotherapy | Drug Treatment of Breast Cancer Questioned--British Study | why chemotherapy increases media survival under 6 months | TOBACCO--NUMBERS OF DEAD AND CAUSES | TOBACCO SMOKE--jk | CHEMICALS FOUND IN TOBACCO AND HEALTH CONSEQUENCES | THE CHEMICAL CAUSE OF CORONARY DISEASE IN SMOKERS | Metastasis, new prophylactic treatment | Cancer risk, standards of evaluation | T-CELL TRIUMPH--success with terminal skin cancer patients | T-cell therapy using modified bacteria | COLON CANCER, an excellent overview | Aspirin & cancer, mechanism, etc. | Coated Aspirin lowers gastric mucosal damage | TERMINAL CANCER--chemotherapy for most types makes little difference | ALTERNATE TREATMENT & INDUCED IMMUNE RESPONSE | 2002 LUNG CANCER STATS | COLON CANCER, sigmoidospy, colonoscopy, & virtual colonoscopy | Basic Facts About Breast Cancer | cancer & methylation

TERMINAL CANCER--chemotherapy for most types makes little difference

 For terminal colon cancer, the chemotherapy group averaged 3.7 more months of being terminally ill.  Is it worth the expense and pain???

Palliative chemotherapy for advanced or metastatic colorectal cancer (Cochrane Review)

Best L, Simmonds P, Baughan C, Buchanan R, Davis C, Fentiman I, George S, Gosney M, Northover J, Williams C. Colorectal Meta-analysis Collaboration

ABSTRACT

A substantive amendment to this systematic review was last made on 16 November 1999. Cochrane reviews are regularly checked and updated if necessary.

Background: Despite the increasing use of palliative chemotherapy for advanced colorectal cancer, there remains uncertainty as to the true effectiveness of this intervention. This review was therefore undertaken to assess the available evidence for the benefit of palliative chemotherapy in this disease.

Objectives: To determine the benefits and harms of palliative chemotherapy in patients with locally advanced or metastatic colorectal cancer. A secondary objective was to investigate outcomes for younger and elderly patients.

Search strategy: Trials were identified by computerised and hand searches of the literature, scanning references and contacting investigators.

Selection criteria: All randomised controlled trials of palliative chemotherapy compared with supportive care alone in patients with advanced or metastatic colorectal cancer.

Both randomised and non-randomised studies were considered when searching for data on quality of life, resource use and cost effectiveness of palliative chemotherapy.

Data collection and analysis: Investigators from all eligible studies were asked to supply individual patient data. Meta-analysis was performed using both published data and individual patient data. Studies were grouped according to whether chemotherapy was administered regionally or systemically.

Main results: 13 randomised controlled trials representing a total of 1365 randomised patients met the inclusion criteria. Meta-analysis of a subset of trials that provided individual patient data demonstrated that palliative chemotherapy was associated with a 35% (95% CI 24% to 44%) reduction in the risk of death [however, they all died shortly—jk]. This translates into an absolute improvement in survival of 16% at both 6 months and 12 months and an improvement in median survival of 3.7 months. [Chemotherapy group averaged 3.7 more months of being terminally ill.  Is it worth the expense and pain???--jk].  The overall quality of evidence relating to treatment toxicity, symptom control and quality of life was poor.

Reviewers' conclusions: Chemotherapy is effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. The survival benefit may be underestimated by this meta-analysis, as a proportion of patients in the control arms of some trials received chemotherapy. No age related differences were found in the effectiveness of chemotherapy, but elderly patients were under represented in trials. Treatment toxicity and impact upon quality of life and symptom control have been inadequately assessed in the majority of trials and further research is needed to clarify the palliative benefit of chemotherapy.

Citation: Best L, Simmonds P, Baughan C, Buchanan R, Davis C, Fentiman I, George S, Gosney M, Northover J, Williams C. Colorectal Meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software.

For most terminal cancers (metastasized aggressive) the scenario is the same as for colon cancer.  New treatments—if there is one—general prolong life only slightly longer than the well research older treatments, and they often cost several times more.

INTERNAL SITE SEARCH ENGINE by Google

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Disclaimer:  The information, facts, and opinions provided here is not a substitute for professional advice.  It only indicates what JK believes, does, or would do.  Always consult your primary care physician for medical advice, diagnosis, and treatment.